Dr. Michael Hamblin, a renowned researcher in photobiomodulation, discusses the slow adoption of PBM therapy as a mainstream treatment, the challenges of conducting expensive clinical trials, and the skepticism among physicians. They also explore the balance between starting low with laser therapy, advancements in light therapy, and the importance of individualized treatment based on patient response.